ALKERMES | ALKS - 债务利息支出

金融业

USD 45.34

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.34B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	债务利息支出	更改		日
AbbVie	USD 746M		101M	2026-06
Acadia Pharmaceuticals	USD 0		4.12M	2024-09
ALKERMES	USD 25.92M		5.03M	2026-06
Amgen	USD 95.64B		94.98B	2026-06
Biogen	USD 72.6M		12.6M	2025-06
BioMarin Pharmaceutical	USD 63.29M		48.34M	2026-06
Bristol-Myers Squibb	USD 403M		4M	2026-09
Coherus Biosciences	USD 2.25M		76K	2025-12
Eli Lilly	USD 316M		201.3M	2026-09
Gilead Sciences	USD 269M		22M	2026-09
Heron Therapeutics	USD 600K		100K	2024-12
Ionis Pharmaceuticals	USD 18M		1000K	2026-06
J&J	USD 43M		25M	2026-03
Merck	USD 525M		46M	2026-06
Minerva Neurosciences	USD 2.31M		60K	2024-06
Nektar Therapeutics	USD 7.94M		1.83M	2026-03
Neurocrine Biosciences	USD 1.1M		0	2024-03
Otsuka Holdings	JPY 2.21B		866M	2025-12
Ovoca Bio	EUR 7K		6K	2022-06
Pfizer	USD 667M		4M	2026-06
Regeneron Pharmaceuticals	USD 11M		1.9M	2026-06
Vertex Pharmaceuticals	USD 3.3M		0	2025-12